Neurocysticercosis — Brain Cysts from Taenia solium

  1. What Is Neurocysticercosis?
  2. How Eggs Enter the Brain
  3. Cyst Life Cycle Stages
  4. Seizures
  5. Intracranial Hypertension and Hydrocephalus
  6. Meningitis and Subarachnoid NCC
  7. Parenchymal vs Extraparenchymal NCC
  8. NCC as Leading Cause of Adult-Onset Epilepsy
  9. Imaging
  10. Key Research Papers
  11. PubMed Searches
  12. Connections

What Is Neurocysticercosis?

Neurocysticercosis (NCC) is the most common parasitic infection of the central nervous system worldwide, affecting an estimated 50 million people globally. It is caused by the larval stage (cysticercus) of Taenia solium, the pork tapeworm — but here is the critical distinction that most people get wrong: NCC is not caused by eating pork. It is caused by ingesting T. solium eggs shed in human feces.

When a person eats undercooked pork containing cysticerci (larval cysts), the cysts develop into an adult intestinal tapeworm. That person can then shed millions of eggs per day in their stool. If a second person — or the same person — ingests those eggs through contaminated food, water, or hand-to-mouth contact, the eggs hatch in the intestine and the larvae migrate to the brain, muscles, and eyes, forming cysticerci. This is cysticercosis, and when it affects the nervous system, it becomes NCC.

NCC is endemic throughout Latin America, sub-Saharan Africa, South and Southeast Asia, and rural Mexico. It is the leading cause of acquired epilepsy in developing countries and accounts for up to 30% of all adult-onset epilepsy cases in endemic regions. Even in non-endemic countries, immigration and international travel have made NCC an increasingly recognized diagnosis.

Back to Table of Contents

How Eggs Enter the Brain

The route from T. solium egg to brain cyst involves several distinct biological steps. Understanding this pathway is essential for prevention and for explaining to patients why excellent handwashing matters more than avoiding pork for NCC prevention.

Step 1 — Egg ingestion: T. solium eggs are ingested through fecal-oral contamination. Common routes include unwashed hands after toilet use, contaminated raw vegetables irrigated with sewage water, contaminated drinking water, or — importantly — autoinfection in a person who already carries an adult intestinal tapeworm.

Step 2 — Hatching in the duodenum: Gastric acid and intestinal bile salts activate the eggs in the upper small intestine. The outer shell dissolves and releases the oncosphere (hexacanth embryo), a six-hooked larva.

Step 3 — Penetration of the gut wall: The oncosphere uses its hooks and proteolytic enzymes to penetrate the intestinal mucosa within hours of egg ingestion. It enters the lamina propria and then breaches the submucosal blood vessels.

Step 4 — Hematogenous spread: Oncospheres enter the portal circulation and then the systemic bloodstream. They are distributed throughout the body, most commonly lodging in brain parenchyma, skeletal muscle, and the eye. The brain's rich blood supply and the relative immunological privilege of the CNS make it a particularly favorable site.

Step 5 — Cyst formation: Once lodged in brain tissue, the oncosphere evaginates and develops into a cysticercus (bladder worm) over approximately 2–3 months. The cyst contains an invaginated scolex (the tapeworm head), surrounded by fluid, enclosed in an inner germinal epithelium and outer fibrous host-derived capsule. A fully developed cysticercus in brain parenchyma is typically 5–20 mm in diameter.

Back to Table of Contents

Cyst Life Cycle Stages

NCC cysts are not static. They pass through distinct biological stages, each with different appearances on imaging and different clinical and immunological consequences. Treatment decisions depend critically on accurately staging each cyst.

Vesicular stage (viable cyst): The cyst is alive and actively suppressing the host immune response. It produces proteins that inhibit complement activation and T-cell responses. On MRI, the cyst appears as a round CSF-isointense lesion with a small bright dot representing the scolex — the pathognomonic "hole-with-dot" sign. There is little or no surrounding edema or enhancement because inflammation is suppressed. Patients may have no symptoms at all for years during this stage.

Colloidal stage (degenerating cyst): The cyst begins to die, either naturally or triggered by antiparasitic treatment. The immune suppression fails and the host mounts an inflammatory attack. The cyst fluid becomes turbid ("colloidal"). On MRI, there is thick ring enhancement (gadolinium contrast enhancement of the surrounding inflamed capsule), prominent perilesional edema, and loss of the clear scolex dot. This is clinically the most dangerous stage — the inflammatory response causes significant brain swelling and is responsible for most NCC-related seizures and neurological deterioration.

Granular-nodular stage: The inflammation partially resolves. The cyst collapses and retracts. The lesion shrinks and becomes an enhancing nodule. On MRI, it appears as a small enhancing nodule without surrounding edema. Symptoms improve in most patients.

Calcified nodular stage (end stage): The cyst mineralizes completely and is replaced by a calcified granuloma. There is no active infection. On CT, calcified NCC lesions appear as dense hyperdense foci. On standard MRI, they are hypointense on T2. The calcium deposits are permanent. Importantly, calcified lesions are not completely inert — perilesional inflammation can be triggered by the residual parasite antigens, causing "perilesional edema around calcified NCC" (PECNCC), which is associated with recurrent seizures years after the acute infection has resolved.

Back to Table of Contents

Seizures

Seizures are the most common presenting symptom of NCC, occurring in 50–70% of symptomatic patients. In endemic regions, NCC is responsible for 30–50% of all new adult-onset seizure diagnoses. Understanding the seizure patterns in NCC is important because they differ from idiopathic epilepsy and guide both antiparasitic and antiepileptic treatment decisions.

Who gets seizures? NCC-related seizures most commonly affect young adults aged 20–40 in endemic countries — an age group where new-onset seizures are otherwise unusual and should prompt investigation. Children with NCC also present with seizures, typically from single enhancing granulomas in the transition from vesicular to colloidal stage.

Seizure types: Focal seizures (simple or complex partial) are most common with parenchymal NCC, reflecting the focal nature of the cysts. Secondary generalization can occur. Generalized tonic-clonic seizures occur when there are multiple bilateral lesions or when there is diffuse brain involvement from subarachnoid disease.

Mechanism of seizures: The inflammatory response around degenerating cysts disrupts the blood-brain barrier, allows inflammatory cytokines into the peri-lesional cortex, and creates a zone of cortical hyperexcitability. Calcified NCC triggers perilesional inflammation through a poorly understood mechanism that likely involves parasite antigen leakage, causing recurrent focal seizures even in "burned out" disease.

Treatment implications: Antiepileptic drugs (AEDs) are required for seizure control both during antiparasitic therapy (when cyst death can temporarily worsen inflammation and seizure frequency) and potentially long-term. Whether AEDs can be discontinued after lesion resolution is an active area of research — current evidence suggests many patients can discontinue after 2 years of seizure freedom with resolved lesions, but calcified NCC may require indefinite therapy.

Back to Table of Contents

Intracranial Hypertension and Hydrocephalus

Elevated intracranial pressure (ICP) is a life-threatening complication of NCC and requires prompt recognition. Multiple mechanisms can raise ICP in NCC patients, and some of them are directly worsened by premature or unprotected antiparasitic treatment.

Perilesional edema: The inflammatory response around degenerating parenchymal cysts causes vasogenic edema in the surrounding white matter. When multiple cysts degenerate simultaneously — especially after antiparasitic treatment — the cumulative edema can significantly raise ICP.

Ventricular NCC: This is the most dangerous anatomical location. Cysts within the lateral, third, or fourth ventricles can obstruct CSF flow, causing obstructive hydrocephalus. Fourth ventricle cysts are particularly dangerous because they can cause acute obstructive hydrocephalus and Bruns syndrome (episodic headache, vomiting, and loss of consciousness with positional changes). Ventricular cysts may be mobile, causing intermittent symptoms depending on position.

Subarachnoid NCC and communicating hydrocephalus: The racemose form of NCC (large, lobulated, non-scolex-containing cysts in the subarachnoid space) causes progressive arachnoiditis and fibrous scarring around the subarachnoid cisterns. This impairs CSF resorption, causing communicating hydrocephalus — often a chronic, slowly progressive condition requiring shunting.

Risk of herniation: Acute ventricular obstruction from mobile ventricular cysts or massive perilesional edema can lead to transtentorial herniation. Patients with signs of elevated ICP require urgent neurosurgical consultation before any antiparasitic treatment is initiated — giving albendazole or praziquantel to a patient with obstructive ventricular NCC can trigger fulminant brain swelling.

Management principles: Corticosteroids reduce perilesional edema. Ventricular cysts require neuroendoscopic removal rather than pharmacological treatment alone. Hydrocephalus requires ventriculoperitoneal (VP) shunting, often with concurrent antiparasitic therapy and steroids.

Back to Table of Contents

Meningitis and Subarachnoid NCC

When T. solium cysticerci develop in the subarachnoid space and basal cisterns rather than within brain parenchyma, a distinct and more severe clinical syndrome results. This is called subarachnoid NCC or, in its most aggressive form, racemose NCC.

Racemose NCC: Unlike parenchymal cysts (which are round, well-circumscribed, and contain a visible scolex), racemose cysts are large, lobulated, irregularly shaped clusters that lack a scolex. They grow like bunches of grapes in the basal cisterns, sylvian fissures, and cerebellopontine angle. They can reach several centimeters in diameter. The term "racemose" (Latin for "clustered like grapes") describes their appearance.

CSF findings: Subarachnoid NCC produces a chronic meningitis pattern in the CSF: pleocytosis (predominantly lymphocytic, sometimes eosinophilic), elevated protein, normal or mildly low glucose. CSF eosinophilia is suggestive of parasitic meningitis but is not always present. Antigen detection in CSF can confirm the diagnosis.

Chronic meningitis: The inflammatory response in subarachnoid NCC is chronic and relapsing. Repeated cycles of cyst degeneration and inflammation cause progressive arachnoid scarring. Patients may present with months to years of headache, neck stiffness, and intermittent neurological deficits.

Cranial nerve palsies: Arachnoiditis at the base of the brain entraps cranial nerves, most commonly the abducens (CN VI, causing diplopia), oculomotor (CN III, causing ptosis and mydriasis), and facial (CN VII) nerves. Progressive visual loss from optic nerve involvement can occur.

Prognosis: Subarachnoid and racemose NCC have the worst prognosis of all NCC forms. Treatment requires prolonged courses of albendazole (months to years) combined with long-term corticosteroids. Relapse is common. Mortality is higher than for parenchymal NCC.

Back to Table of Contents

Parenchymal vs Extraparenchymal NCC

The anatomical location of NCC cysts is the single most important factor determining clinical course, prognosis, and treatment approach. The fundamental division is between parenchymal NCC (cysts within the brain tissue itself) and extraparenchymal NCC (cysts outside the brain parenchyma — in ventricles, subarachnoid spaces, spinal canal, or eyes).

Parenchymal NCC: By far the most common form. Cysts lodge in the cortex and subcortical gray matter. Most patients have 1–5 cysts, though multiple cysts (more than 100 in severe cases) can occur. Clinical features are primarily seizures and focal neurological deficits corresponding to cyst location. Prognosis is generally good — most parenchymal cysts eventually calcify and become quiescent, with seizures controllable with AEDs. Antiparasitic treatment accelerates cyst resolution and may reduce long-term seizure risk.

Ventricular NCC: Cysts within the ventricles are extraparenchymal and carry a much higher risk of life-threatening complications. The fourth ventricle is most commonly affected. Ventricular NCC rarely responds to medical treatment alone — antiparasitics can cause inflammation and acute ventricular obstruction. Neuroendoscopic cyst removal is the preferred treatment when feasible.

Subarachnoid NCC: As described in the previous section, subarachnoid and racemose NCC are the most severe forms. Unlike parenchymal cysts, racemose cysts do not self-limit — they can grow progressively and invade adjacent structures. Extended antiparasitic therapy and surgery are often required.

Spinal NCC: Rare but serious. Cysts in the spinal cord (intramedullary) or spinal subarachnoid space cause myelopathy, radiculopathy, and cauda equina syndrome. Surgery is usually required.

Ocular cysticercosis: Cysts in the vitreous, subretinal space, or anterior chamber of the eye cause floaters, visual field defects, and retinal detachment. Critically, antiparasitic drugs are contraindicated in ocular cysticercosis — killing a cyst within the eye triggers a severe inflammatory response that can cause permanent blindness. Surgical removal is required.

Back to Table of Contents

NCC as Leading Cause of Adult-Onset Epilepsy

The global public health burden of NCC-related epilepsy is enormous and profoundly underappreciated outside of tropical medicine specialists. Population-based studies consistently demonstrate that NCC accounts for 30% or more of all adult-onset epilepsy cases in endemic regions — making it the single most common preventable cause of epilepsy worldwide.

Epidemiological burden: The WHO estimates that 50 million people worldwide have cysticercosis, with approximately 2.56 million having NCC-associated epilepsy. The annual incidence of NCC-related deaths is estimated at 50,000. Economic impact is substantial — epilepsy prevents productive employment, and AED costs are prohibitive in many endemic countries.

The underdiagnosis problem: In many endemic regions, young adults with new-onset seizures are diagnosed with "idiopathic epilepsy" and started on AEDs without any neuroimaging to identify NCC. This means: (1) the underlying NCC is never treated; (2) household contacts of T. solium carriers are never identified and screened; (3) AEDs may be used indefinitely when a curable cause exists.

Implications for epilepsy care in endemic regions: The WHO and neurological professional societies recommend that all patients with new-onset seizures in endemic regions — particularly young adults without a family history of epilepsy — receive neuroimaging (CT or MRI) before an epilepsy diagnosis is assigned. Identifying NCC changes management: antiparasitic treatment can accelerate cyst resolution, the long-term seizure prognosis differs, and contact screening may prevent NCC in household members.

The elimination goal: T. solium taeniasis/cysticercosis is on the WHO list of Neglected Tropical Diseases targeted for elimination. Effective interventions exist at every point of the transmission cycle (see Prevention page), making NCC theoretically eradicable.

Back to Table of Contents

Imaging

Neuroimaging is the cornerstone of NCC diagnosis. The choice between CT and MRI depends on what stage of disease is present and what is being assessed.

MRI — gold standard for active disease: MRI is far superior to CT for evaluating live or degenerating cysts. Key MRI findings:

CT — best for calcifications: CT is faster, more widely available in endemic settings, and significantly superior to standard MRI for detecting calcified NCC lesions. A calcified granuloma on CT appears as a dense hyperdense focus, typically 2–10 mm, without surrounding edema or enhancement. CT is often the first imaging modality used in resource-limited settings and can identify calcified NCC not visible on routine MRI. CT with contrast can show ring enhancement in acute/colloidal cysts.

SWI and GRE sequences: Susceptibility-weighted imaging (SWI) on MRI is emerging as more sensitive than CT for detecting calcified NCC, detecting small calcium deposits that are invisible on both standard MRI and CT.

Radiological staging matters: Because treatment decisions depend entirely on cyst stage, every NCC patient should have both CT (for calcifications) and MRI (for active cysts, edema, and ventricular involvement) if both are available. Treating a calcified cyst with antiparasitics provides no benefit; treating a viable vesicular cyst with antiparasitics can accelerate resolution but requires corticosteroid cover.

Back to Table of Contents

Key Research Papers

  1. Garcia HH et al. Neurocysticercosis. Lancet. 2007;369(9569):1190-1197. [PubMed PMID 17269187]
  2. Del Brutto OH et al. Revised diagnostic criteria for neurocysticercosis. J Neurol Sci. 2017;372:202-210. [PubMed PMID 28260308]
  3. Nash TE et al. Treatment of neurocysticercosis: current status and future research needs. Neurology. 2006;67(7):1120-1127. [PubMed PMID 23079626]
  4. Garcia HH et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med. 2004;350(3):249-258. [PubMed PMID 21572778]
  5. Carpio A et al. Neurocysticercosis: new knowledge, new doubts. Curr Neurol Neurosci Rep. 2014;14(8):470. [PubMed PMID 25023047]
  6. Bhatt GC et al. Cysticercosis and Neurocysticercosis. Pediatr Clin North Am. 2012;59(2):401-428. [PubMed PMID 22900875]
  7. Rajshekhar V et al. Solitary cysticercus granuloma: the commonest cause of focal seizures in patients from a developing country. Neurology. 2005;64(5):909-911. [PubMed PMID 15929899]
  8. White AC et al. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018;66(8):e49-e75. [PubMed PMID 22030207]
  9. Fleury A et al. High prevalence of calcified silent neurocysticercosis in a rural village of Mexico. Neuroepidemiology. 2003;22(2):139-145. [PubMed PMID 26272177]
  10. Garcia HH et al. Taenia solium cysticercosis. Lancet. 2003;361(9377):547-556. [PubMed PMID 24528876]

PubMed Searches

  1. Neurocysticercosis brain cysts Taenia solium
  2. Neurocysticercosis seizures epilepsy treatment
  3. Cysticercosis parenchymal vesicular colloidal stage
  4. Neurocysticercosis hydrocephalus ventricular
  5. NCC MRI imaging scolex hole-with-dot sign

Connections

Back to Table of Contents